After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...
In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Pirtobrutinib showed an 80% reduction in PFS compared with BendaR in treatment-naïve CLL/SLL patients, indicating its potential as a first-line therapy. The trial demonstrated pirtobrutinib's superior ...
About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...
(RTTNews) - BeOne Medicines Ltd. (ONC) Thursday announced it presented new clinical data at the 2025 European Hematology Association or EHA Congress, highlighting the potential of its next-generation ...
Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests. Research into immunotherapy against cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results